A new era in cancer care: The Bay Area's role in ending cancer for all
Cancer doesn't wait. Neither can we.
A legacy of Bay Area innovation and impact
Since 2011, the San Francisco Discovery Gala has channeled the Bay Area's entrepreneurial spirit into nearly $19 million to support breakthrough research, essential patient services, and effective advocacy. In 2023, it earned recognition as the American Cancer Society's Event of the Year — a testament to the Bay Area's distinctive ability to drive transformative change.
This signature event exemplifies what's possible when the region's visionary business leaders and passionate advocates unite for a common purpose. Distinguished past event chairs and sponsors represent many of the Bay Area's most influential employers, whose strategic partnerships continue to fuel ACS's life-saving work both locally and nationally.
Our mission: Measurable results
ACS stands as the largest private nonprofit funder of cancer research in the United States, with strategic investments exceeding $3.1 billion since 1991. This commitment has helped drive a remarkable 34% reduction in cancer mortality rates and prevented 4.5 million cancer deaths between 1991 and 2021. In 2024 alone, our mission positively impacted over 140.5 million lives through patient support, advocacy, and education.*
More than 80 cents of every dollar donated directly supports programs that empower people to prevent, detect, treat, and survive cancer. ACS benefits from the expertise of over 1 million volunteers in communities across the U.S., Puerto Rico, and Guam. Their invaluable contributions in 2024 represented more than $522 million in wage replacement value.*
expand
Cory Goodale
Prevention and detection: Progress and opportunity
The Cancer Prevention and Early Detection Facts & Figures 2025–2026 report reveals important gains while highlighting critical opportunities. Breast and colorectal cancer screening rates have successfully rebounded post-pandemic, and smoking rates continue their encouraging decline.
However, cervical cancer screening remains below optimal levels, and HPV vaccination rates have plateaued. Meanwhile, excess body weight, physical inactivity, and alcohol consumption present persistent public health challenges. ACS remains dedicated to expanding access to prevention and early detection tools, with particular focus on historically underserved populations.
"We're witnessing meaningful progress," notes Priti Bandi, Ph.D., ACS scientific director, "but now is precisely the time for Bay Area leaders to double down — especially on HPV and cervical cancer prevention."
California's strategic imperative
California faces one of the nation's most significant cancer challenges: projections indicate over 199,000 new diagnoses in 2025, with an estimated 60,000 cancer-related deaths.* These sobering numbers underscore the urgent need for continued investment and Bay Area leadership in the fight against cancer.
Bay Area innovation, national impact
Proceeds from the San Francisco Discovery Gala strengthen ACS's robust $400 million research portfolio, including more than 600 active grants nationwide — many based within premier Bay Area research institutions.* ACS-funded researchers are pioneering breakthroughs in treatment, early detection, and survivorship that will fundamentally reshape cancer care for everyone.
Our comprehensive services reached 75% of U.S. ZIP codes in 2024, providing critical transportation, lodging, and personalized support.* Our advocacy network extends across every state and territory, ensuring policy solutions that remove barriers to care and strengthen protections for everyone affected by cancer.
expand
Cory Goodale
Strategic partnership opportunities
ACS cultivates high-impact collaborations with health systems, nonprofits, and corporate leaders to expand access to cancer care and education. These strategic partnerships are central to our work advancing health equity, prevention, and workforce engagement.
In 2024 alone, we responded to more than 26,000 cancer information helpline calls in California, provided over 31,000 transportation services, delivered over 2,500 nights of free lodging, and facilitated direct navigation to care for thousands of residents.*
Young leaders addressing urgent trends
Cancer rates are increasing among adults under 50, a trend particularly relevant to Bay Area's young professional demographic. According to Cancer Facts & Figures 2025, cancers, including breast and colorectal, are rising among younger adults. This emerging challenge highlights the importance of initiatives like Fork Cancer Bay Area, led by the Associate Board of Ambassadors. This dynamic network of young professionals brings fresh perspective and long-term commitment to our mission, providing Bay Area companies with engagement opportunities for their emerging leaders.
Join Bay Area leaders in the fight
We invite Bay Area executives to distinguish themselves by joining the exclusive CEOs Against Cancer Bay Area Chapter. This influential network of senior leaders is advancing workplace wellness and community health through direct partnership with ACS. Members commit to building a best-in-class health culture while driving toward specific screening and prevention goals that benefit both their organizations and communities.
Membership includes:
Two annual high-level chapter meetings with fellow Bay Area executives
An appointed executive liaison to seamlessly integrate wellness initiatives enterprise-wide
Turnkey engagement toolkits and communications support to maximize impact
Access to exclusive networking and community events with the region's most influential leaders
With 83% of employers listing cancer among their top three health care cost drivers — and 74% of patients missing work, often four weeks or more — a healthier workforce isn't just a mission priority.* It's a compelling business imperative for Bay Area companies focused on talent retention and productivity.
Lead the way forward
The 2025 San Francisco Discovery Gala, taking place Sept. 27 at Chase Center, represents more than a premier social event — it's the cornerstone of a year-round movement. Strategic sponsorship connects your brand to measurable impact-driven outcomes and aligns your business with one of the most trusted and influential cancer-fighting organizations in the world.
Together, the Bay Area's most innovative companies and visionary leaders can shape a future where fewer lives are lost and every person has the opportunity to live a longer, healthier life.
Explore our comprehensive corporate partnership opportunities at cancer.org/becomeapartner or contact Leslie Irwin at leslie.irwin@cancer.org to discuss a customized engagement strategy.
To secure your place among Bay Area leaders at the San Francisco Discovery Gala, visit sfdiscoverygala.org or reach out to Leah Malfatti at leah.malfatti@cancer.org.
*According to American Cancer Society
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
a day ago
- Fox News
Colorectal cancer may cause these 4 hidden warning signs, experts say
Colorectal cancer rates have soared among younger Americans, new research has found — and there might not always be obvious symptoms. The lifetime risk of developing colorectal cancer (CRC) is one in 24 for men and one in 26 for women, according to the American Cancer Society. It is the third-leading cause of cancer-related deaths in men and the fourth in women, but is the second most common cause when the numbers for men and women are combined. While there may be no symptoms of CRC before diagnosis, especially in the early stages, the following signs and symptoms should not be overlooked, experts say. According to the Colorectal Cancer Alliance, some symptoms of the disease can be similar to other causes, like hemorrhoids, infection or irritable bowel syndrome (IBS). But a change in bowel habits — including diarrhea, constipation, narrow stools or feeling like your bowels are full even after a movement — can be a sign of CRC. Fight Colorectal Cancer, a leading patient advocacy group, noted on its website how bowel movements can change due to diet, infections, medications and other medical issues. A change in bowel movement schedule or stool appearance could also signal CRC. Fight CRC recommends calling a doctor if your stool is consistently abnormal, if you have sudden urges to pass stool but can't control it, if the stool is black, clay-colored, red or white, or if there is mucus or pus in the stool. Skinny, thin or pencil-like stool may also indicate an obstruction in the colon, like a tumor, but can also be caused by other harmless, temporary conditions. Persistent discomfort in the abdomen is another CRC symptom, the Colorectal Cancer Alliance reported on its site. This can include feelings of pain, nausea, cramping, bloating or feeling unusually full, even after not eating much. Severe, "knife-in-my-stomach type" abdominal pains warrant a visit to the emergency room, Fight CRC instructed — but even mild pains shouldn't be taken lightly. Blood in the stool, toilet or when wiping with toilet paper can be a major sign of colorectal cancer. Fight CRC stressed that any amount of rectal bleeding is not normal and should be brought to a doctor's attention for proper diagnosis. Since blood in the stool is a common symptom, Fight CRC instructed paying attention to where the blood is found, how often it occurs and whether bowel movements are painful. Unexplained weight loss can sometimes be caused by cancer and should be brought to the attention of a doctor, according to the Colorectal Cancer Alliance. Weight loss is the result of cancer cells "consuming the body's energy" as they multiply, Fight CRC explained, as the immune system expends more energy to fight and destroy cancer cells. This can also lead to feeling fatigue, weakness or shortness of breath. For more Health articles, visit These symptoms may also be a sign of anemia, which can develop from bleeding somewhere inside the body, like from a cancerous tumor. Weight loss can also be caused by a tumor blocking the colon or intestinal tract, which prevents proper nutrient absorption.
Medscape
a day ago
- Medscape
Cervical Cancer: 5 Things to Know
Cervical cancer remains a significant global health concern, ranking as the fourth most common cancer in women worldwide, with an estimated 660,000 new cases and 350,000 deaths in 2022. The burden is unevenly distributed, with over 85% of cases occurring in low- and middle-income countries, where access to preventive care and treatment is limited. In contrast, the incidence and mortality rates in the United States have declined substantially due to widespread implementation of cervical cancer screening programs and human papillomavirus (HPV) vaccination, with an estimated 13,820 new cases and 4,360 deaths expected in the US in 2024. Cervical cancer develops from a multistep transformation process triggered by persistent infection with high-risk types of HPV, most notably HPV 16 and 18. These oncogenic strains integrate into host DNA, expressing viral proteins E6 and E7, which inactivate the tumor suppressors p53 and retinoblastoma protein (Rb), respectively, and promote genomic instability. The progression from infection to cervical intraepithelial neoplasia and eventually invasive carcinoma may take 15-20 years after initial HPV infection, providing a window for early detection and prevention. Histologically, the majority of cervical cancers are squamous cell carcinomas (~80%), followed by adenocarcinomas and adenosquamous carcinomas. The World Health Organization now distinguishes between HPV-associated and HPV-independent tumors, with the latter comprising roughly 5% of cases — often displaying worse outcomes and distinct molecular profiles — although current treatment strategies do not yet differ based on HPV status. Here are five things to know about Cervical Cancer. 1. HPV vaccination and screening remain the most powerful tools for prevention. Persistent infection with oncogenic HPV types, particularly HPV 16 and 18, is responsible for over 95% of cervical cancers. Screening and vaccination efforts have significantly reduced cervical cancer incidence in countries with established programs. According to 2018 recommendations from the United States Preventive Services Task Force, women aged 21-29 should undergo cervical cytology (Pap smear) every 3 years, while those aged 30-65 may choose between cytology every 3 years, high-risk HPV testing every 5 years, or cotesting every 5 years. In contrast, the American Cancer Society's 2020 guidelines recommend beginning screening at age 25 with HPV testing as the preferred method. No routine screening is recommended for women younger than 21, older than 65, or those who have undergone a hysterectomy for benign reasons. HPV vaccination has transformed cervical cancer prevention. Vaccination before the age of 17 has been shown to reduce cervical cancer incidence by nearly 90%, and growing evidence supports that a single dose may be as effective as a full series, which could simplify implementation in low-resource settings. 2. At-home HPV testing is a breakthrough in improving access. To expand screening to underserved populations, the FDA approved clinician-supervised self-collected HPV testing in 2024 and fully at-home HPV testing in 2025. These regulatory changes represent a major shift in cervical cancer screening accessibility. Clinical trials have demonstrated that the sensitivity of at-home HPV testing of ~95% is equivalent to that of clinician-collected samples. This development is especially important for increasing screening rates in medically underserved communities, including individuals with limited access to healthcare, cultural stigma surrounding pelvic exams, or logistical barriers to in-person visits. By reducing these obstacles, at-home HPV testing has the potential to improve early detection, narrow disparities, and prevent progression to advanced cervical cancer among those most at risk. 3. HPV is the primary risk factor, but others contribute to disease development. While infection with high-risk HPV is a necessary precursor to most cervical cancers, not all women with HPV will develop cancer. Additional factors can influence progression from transient infection to persistent infection, dysplasia, and ultimately malignancy. Tobacco use is among the most well-established risk factors, doubling the risk of squamous cell carcinoma by impairing local immune defenses in the cervix. Immunosuppression, especially in individuals with the human immunodeficiency virus, markedly increases the risk of persistent HPV infection and cervical dysplasia. Other contributing factors include chronic chlamydia infection, long-term use of oral contraceptives, having three or more full-term pregnancies, early age at first childbirth, poor diet lacking in fruits and vegetables, and exposure to diethylstilbestrol in utero. Lower socioeconomic status is consistently associated with higher cervical cancer incidence and worse outcomes, largely due to reduced access to screening and timely care. Though uncommon, a subset of cervical cancers (3%-8%) are not associated with HPV and tend to present at older ages, potentially with more aggressive biology. 4. Symptoms often appear late, making screening critical. Most early cervical cancers and pre-cancerous lesions are asymptomatic, which is why regular screening is vital for early detection. When symptoms do occur, they often include abnormal vaginal bleeding, such as post-coital or intermenstrual bleeding, watery or malodorous vaginal discharge, pelvic pain, and dyspareunia. As the disease advances, more severe symptoms may develop, including urinary symptoms, lower abdominal pressure, hematuria, and hematochezia depending on the site of metastasis. Diagnosis is initiated with colposcopy and biopsy following abnormal screening results. Biopsies may include punch biopsy, endocervical curettage, or cone biopsy depending on lesion size and location. Once cancer is confirmed, staging typically involves pelvic examination, imaging such as MRI or PET-CT, and sometimes examination under anesthesia. Cervical cancer is staged using the International Federation of Gynecology and Obstetrics system, which incorporates clinical and radiologic findings to guide treatment decisions. Lack of participation in cervical cancer screening is a key reason for late-stage diagnosis, highlighting the critical need to improve screening uptake and address missed opportunities for early detection. 5. Treatment is stage-specific and increasingly personalized. Treatment of cervical cancer depends on disease stage, type of cervical cancer, patient comorbidities and age, desire for fertility preservation, and whether the cancer has just been diagnosed or has recurred. For patients with microinvasive disease (stage IA1), options include cold knife conization if the depth of invasion is < 3 mm or total hysterectomy. Stages IA2-IB2 are typically managed with radical hysterectomy and pelvic lymphadenectomy, although fertility-sparing surgery such as radical trachelectomy may be considered in select patients; intracavitary radiation therapy may be considered as a palliative option for women who are not eligible for surgery or have medical contraindications to other treatments. Locally advanced disease (stages IB3-IVA) is treated with definitive chemoradiation, usually consisting of external beam radiation therapy combined with weekly cisplatin. Brachytherapy is an essential component of treatment for curative intent. Recent data suggest that induction chemotherapy before chemoradiation may improve survival outcomes in some patients, although this approach is still under investigation. For recurrent or metastatic disease, systemic therapy with or without palliative radiation is the mainstay. First-line therapy often includes a combination of platinum-based chemotherapy, paclitaxel, and the antiangiogenic agent bevacizumab. For patients with PD-L1-positive tumors, the addition of pembrolizumab, with or without bevacizumab, to chemotherapy has become standard of care based on the KEYNOTE-826 trial. In the second-line setting, options expand to include other cytotoxic agents such as topotecan, gemcitabine, or vinorelbine, as well as immunotherapy and targeted agents. In pregnancy, treatment strategies depend on cancer stage and gestational age, often balancing maternal prognosis with fetal viability.
Newsweek
2 days ago
- Newsweek
Millennial Spent the Summer Gardening in Yard, Then Came Shocking Diagnosis
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. "I know exactly how I got skin cancer. And I promise it could happen to you as well." That is the warning from 37-year-old April Catudal, who was recently diagnosed with Stage IA melanoma earlier this summer. The mom who lives in Roswell, Georgia, had never had any issues in previous exams. But, this year, her dermatologist noticed something different. "I was diagnosed earlier this summer after going in for my yearly skin exam in early June," Catudal told Newsweek. "My dermatologist immediately saw the mole and biopsied it, though he didn't expect it to be melanoma since it was an old mole that had grown in size. The biopsy came back as Stage IA melanoma." The diagnosis came as a shock—not because of any visible warning signs, but because of what she now realizes was a blind spot in her approach to sun safety. "The reason I decided to share is because I had been really naive about how important it is to protect my skin," Catudal said. "I thought I needed to absorb vitamin D, and also I had never had even one annual skin test come back as abnormal, so I had developed a lot of false confidence." Catudal said she hadn't considered herself high risk. She didn't use tanning beds, never had a bad burn in adulthood, and assumed that brief time in the sun wasn't dangerous. She also hadn't been aware of how prevalent skin cancer is, or how serious even early-stage melanoma can be. "I didn't know the skin cancer stats in the U.S., and I also wasn't aware of the emotional and physical toll the diagnosis would have on me, and I truly was as lucky as can be," Catudal added. A picture from the viral video where April shared her skin-cancer story. A picture from the viral video where April shared her skin-cancer story. @naturallyapril/Instagram Skin-Cancer Risk Factors The American Cancer Society's 2025 Cancer Statistics report an estimated 104,960 new cases of invasive melanoma are expected to be diagnosed in the United States this year, including 60,550 in men and 44,410 in women. Around 8,430 Americans (5,470 men and 2,960 women) are projected to die from the disease. The American Cancer Society says that exposure to ultraviolet rays is the biggest major risk factor for most melanomas. UV rays damage the DNA inside skin cells, and skin cancers can begin when this damage affects the genes that control skin cell growth. Around 1 in 10 people with melanoma have a family history of the disease, while there is also evidence that people with lighter skin colors and hair are more at risk. Catudal said she now believes she knows exactly how she got skin cancer, and it wasn't from tanning beds or sunbathing. It was gardening. "I was planting away all spring, removing old pine straw and planting new flower beds, bent with my neck directly exposed to the hot sun for hours at a time," Catudal said. "Dumb." While her dermatologist couldn't say definitively, he told her it could have been caused by either years of accumulated DNA damage or from a single repeated action, like that intense spring spent outdoors. "To be honest, my dermatologist said there's no way of knowing if it's years of accumulated skin DNA damage or way too much exposure from one repeated action (gardening)," Catudal said. What felt like harmless time in the sun—without sunscreen on just one spot—may have been all it took. Catudal's neck, left uncovered during hours in the yard, was where the melanoma appeared. And it is a mistake that many people make without realizing the potential cost. Catudal had the mole removed and is now cancer-free, but the diagnosis left a lasting impact and prompted her to share her story with others. "Either way, I'm just so relieved that I had stayed on top of my yearly exam, even though life was crazy," she said. "And now I'm so very grateful that I get to share my story, help other women in their relative prime stay safe and take care of their skin."
